Tag: AKBA

Finance

Healthcare Unusual Volume: Edwards Lifesciences Corp (NYSE:EW), Allergan (NYSE:AGN), Akebia Therapeutics (NASDAQ:AKBA), Acorda Therapeutics (NASDAQ:ACOR)

Edwards Lifesciences Corp (NYSE:EW) climbed 11 percent after the company won a court ruling that limited the sale of Medtronic’s (MDT) CoreValve system in the US. Edwards Lifesciences Corp (NYSE:EW) stock performance was 11.00% in last session and finished the day at $81.00. Traded volume was 7.23million shares in the last session and the average volume of the stock remained 1.36million shares. The beta of … Continue reading Healthcare Unusual Volume: Edwards Lifesciences Corp (NYSE:EW), Allergan (NYSE:AGN), Akebia Therapeutics (NASDAQ:AKBA), Acorda Therapeutics (NASDAQ:ACOR)

Colin Pettis
Finance

Healthcare Stocks Touched New Lows: VIVUS (NASDAQ:VVUS), Akebia Therapeutics Inc (NASDAQ:AKBA), Versartis Inc (NASDAQ:VSAR), BioLife Solutions (NASDAQ:BLFS)

VIVUS Inc. (NASDAQ:VVUS) lower following news late Tuesday night that three directors — J. Martin Carroll, Mark B. Logan and Robert N. Wilson — will not stand for re-election to the company’s Board. This will be the sixth-straight session for the stock to close lower. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 0.20% in last session and finished the day at $5.00. Traded volume was 2.64million … Continue reading Healthcare Stocks Touched New Lows: VIVUS (NASDAQ:VVUS), Akebia Therapeutics Inc (NASDAQ:AKBA), Versartis Inc (NASDAQ:VSAR), BioLife Solutions (NASDAQ:BLFS)

Kristen Barton
Finance

Biotech New Lows: Akebia Therapeutics (NASDAQ:AKBA), Galmed Pharmaceuticals (NASDAQ:GLMD), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Dipexium Pharmaceuticals (NASDAQ:DPRX)

Akebia Therapeutics Inc. (NASDAQ:AKBA) offered 5.9 million shares in its Thursday IPO at $17 a share, the high end of the stock’s expected price range. Among other therapeutics, the biopharma company is developing a once-daily oral therapy for patients with kidney disease. Akebia Therapeutics, Inc. (NASDAQ:AKBA) stock performance was -0.99% in last session and finished the day at $20.00. Traded volume was 219,904 million shares … Continue reading Biotech New Lows: Akebia Therapeutics (NASDAQ:AKBA), Galmed Pharmaceuticals (NASDAQ:GLMD), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Dipexium Pharmaceuticals (NASDAQ:DPRX)

Kevin Long
Finance

Stocks in News: Kinross (NYSE:KGC), Blonder Tongue Laboratories (NYSEMKT: BDR), Akebia Therapeutics (NASDAQ:AKBA), Rofin-Sinar (NASDAQ:RSTI), CarMax (NYSE:KMX)

Gold miner Kinross Gold Corporation (NYSE:KGC) posted adjusted earnings of $32.9 million or 3 cents per share in the second quarter of 2014, down 72.5% from adjusted earnings of $119.5 million or 10 cents per share in the year-ago quarter. Earnings per share also missed the Zacks Consensus Estimate of 4 cents per share. Kinross Gold Corporation (NYSE:KGC) belongs to Basic Materials sector. Its weekly … Continue reading Stocks in News: Kinross (NYSE:KGC), Blonder Tongue Laboratories (NYSEMKT: BDR), Akebia Therapeutics (NASDAQ:AKBA), Rofin-Sinar (NASDAQ:RSTI), CarMax (NYSE:KMX)

Jason Knox